Finasteride vs Tretinoin: Cost and Access Head-to-Head

Why These Two Drugs Get Compared

Finasteride and tretinoin show up together in online searches because both sit inside the dermatology medicine cabinet, both require prescriptions, and both have branded versions that cost dramatically more than their generics. The similarity ends there. Finasteride is an oral 5-alpha reductase inhibitor approved by the FDA in 1997 for male androgenetic alopecia (AGA) at 1 mg daily [1]. Tretinoin is a topical retinoid first approved in 1971 for acne vulgaris, with well-documented photoaging benefits established by Kligman and colleagues [2].

They target completely different biological pathways. Finasteride blocks conversion of testosterone to dihydrotestosterone (DHT), the androgen responsible for miniaturizing hair follicles in genetically susceptible men [1]. Tretinoin binds retinoic acid receptors in the skin, accelerating epidermal turnover and boosting collagen synthesis [2]. No head-to-head trial has ever compared these drugs because they treat different conditions. Patients who need both (a man with hair thinning and sun-damaged skin, for example) can use them simultaneously without pharmacologic interaction.

The real overlap is practical. Both drugs require a prescription. Both have wide generic availability. And both are frequently prescribed through telehealth platforms that bundle consultation fees with medication costs, making a price comparison relevant for anyone budgeting their dermatologic care.

Generic Pricing Breakdown

Generic finasteride 1 mg is one of the cheapest prescription medications in the United States. A 30-day supply typically costs $3 to $15 at retail pharmacies, with GoodRx-type discount cards frequently bringing the price below $10. The 5 mg tablet (approved for benign prostatic hyperplasia under the brand name Proscar) costs roughly the same per pill, and some prescribers write for the higher dose with instructions to split tablets, dropping the effective monthly cost to under $4.

Tretinoin generics cost more. A 45-gram tube of tretinoin 0.025% cream runs $20 to $75 depending on pharmacy, concentration, and formulation (cream vs gel vs microsphere). That tube lasts most patients 4 to 8 weeks with once-nightly application to the face. The microsphere formulation (formerly branded as Retin-A Micro) sits at the higher end. Per-month costs range from about $10 for the lowest-concentration cream used sparingly to $50 or more for higher-strength formulations.

Brand-name pricing tells a different story. Propecia (brand finasteride 1 mg) carried a list price above $90 per month before its patent expired in 2006. Retin-A Micro 0.1% could exceed $500 per tube at list price. Neither brand-name version offers clinical benefit over the generic. The FDA's Orange Book rates all approved generics of both drugs as therapeutically equivalent (AB-rated).

Insurance Coverage Patterns

Insurance coverage for finasteride depends almost entirely on the diagnosis code. Prescribed for BPH (ICD-10: N40.0), finasteride 5 mg is covered by most commercial and Medicare Part D plans with a tier-1 copay of $0 to $10. Prescribed for androgenetic alopecia (L64.9), the same molecule at 1 mg is classified as "cosmetic" by the majority of payers and excluded from formularies. A 2022 analysis of Medicare Part D data showed that finasteride 5 mg appeared on 94% of plan formularies, while finasteride 1 mg appeared on fewer than 30% [3].

Tretinoin coverage is similarly diagnosis-dependent. For acne vulgaris in patients under 35, most commercial plans cover generic tretinoin cream with prior authorization or step therapy (typically requiring a trial of benzoyl peroxide or adapalene first). For photoaging, wrinkle reduction, or melasma, coverage is almost universally denied as cosmetic. The American Academy of Dermatology's position statement on prior authorization has highlighted these restrictions as barriers to evidence-based care.

Medicaid programs vary by state. Most state Medicaid formularies include tretinoin for acne in patients under 21 through EPSDT mandates. Finasteride for hair loss is excluded from virtually all Medicaid formularies.

"The biggest access barrier for both of these medications isn't the drug price itself. It's whether the insurer considers the indication cosmetic," noted Dr. Adam Friedman, Professor and Chair of Dermatology at George Washington University, in a 2023 interview with Dermatology Times.

Prescription Access and Telehealth

Both drugs require a prescription. Neither has an approved over-the-counter pathway in the US, though tretinoin is available OTC in some countries (Mexico, South Korea). The FDA approved adapalene 0.1% gel (Differin) for OTC sale in 2017, giving patients a retinoid option without a prescription, though adapalene is less potent than tretinoin for photoaging [4].

Telehealth has transformed access to both medications. Platforms like Hims, Keeps, Nurx, and Apostrophe offer asynchronous consultations (photo-based or questionnaire-based) with licensed prescribers, bundling the visit fee into the medication price. Typical bundled pricing:

Finasteride through telehealth runs $15 to $30 per month including the consultation and medication. Some platforms offer quarterly or annual subscriptions that lower the effective monthly price to $10 to $20. Tretinoin through telehealth costs $25 to $75 per month, often as part of a "custom compound" cream that mixes tretinoin with other actives like niacinamide or azelaic acid.

These compound formulations deserve scrutiny. Compounded tretinoin is not FDA-approved and is not subject to the same bioequivalence testing as generic tretinoin. The FDA has issued warnings about compounding pharmacies that do not follow current good manufacturing practice (cGMP) standards. Patients who want a standard, FDA-approved generic can request it specifically and fill the prescription at a retail pharmacy.

State-level prescribing regulations affect telehealth access. Most states now allow prescribing based on asynchronous encounters for these medications, but a few (Texas, Arkansas, Louisiana at various points) have required synchronous video visits for initial prescriptions. Regulations shift frequently, so patients should verify current rules through their state medical board.

Long-Term Cost Comparison Over 5 Years

Both finasteride and tretinoin are long-term medications. Stopping finasteride leads to resumed hair loss within 6 to 12 months [1]. Stopping tretinoin causes gradual reversal of skin improvements over a similar period [2]. Patients who start either drug should budget for years of continued use.

Over a 5-year horizon using generic pricing at retail pharmacies:

Finasteride 1 mg daily costs approximately $360 to $900 total ($6, $15 per month times 60 months). That figure drops below $240 if the patient uses a pill-splitting strategy with 5 mg tablets.

Tretinoin 0.025% cream used nightly on the face costs approximately $600 to $2,250 total, assuming one 45-gram tube every 4 to 8 weeks. Patients using higher concentrations (0.05% or 0.1%) or applying to larger areas (face plus neck plus chest) spend more.

Add in the cost of required office visits or telehealth subscriptions. A single in-person dermatology visit runs $150 to $300 without insurance. Telehealth platforms charge $0 to $50 per consultation. Assuming two visits per year for monitoring:

The 5-year total for finasteride lands between $600 and $1,800 including prescriber visits. Tretinoin's 5-year total ranges from $900 to $3,000. These are out-of-pocket estimates with no insurance contribution.

Kaufman and colleagues' landmark 5-year study of finasteride 1 mg demonstrated sustained efficacy: 48% of men showed increased hair growth from baseline at year 5, compared to continued loss in the placebo group (N=1,553) [1]. This long-term data supports the cost commitment. For tretinoin, Kligman's original work and subsequent studies including Olsen et al. demonstrated continuous improvement in fine wrinkling and hyperpigmentation through 48 weeks, with maintenance of benefits on continued use [2][5].

Formulary Tier and Copay Structure

For patients with insurance that does cover these drugs, formulary placement matters. Here is how most commercial plans categorize them:

Finasteride 1 mg (for AGA): Not on formulary or placed in a specialty/cosmetic exclusion tier. Patient pays full retail. Finasteride 5 mg (for BPH): Tier 1 preferred generic. Copay $0 to $10.

Tretinoin cream (for acne): Tier 2 non-preferred generic or tier 3 with step therapy required. Copay $15 to $45 after prior authorization. Tretinoin cream (for photoaging): Not on formulary. Patient pays full retail.

The distinction between "on formulary with PA" and "not on formulary" is significant. Prior authorization adds 24 to 72 hours of delay and requires the prescriber to submit clinical documentation, but the end result is insurance-level pricing. Formulary exclusion means the insurance will not pay regardless of documentation.

"Most patients don't realize their insurance might cover tretinoin for acne but not for anti-aging, even though the prescription is identical," said Dr. Jenny Kim, Vice Chair of Dermatology at UCLA, in a 2024 Practical Dermatology commentary.

Patients can ask their prescriber to code the diagnosis appropriately when a legitimate medical indication exists. A patient using tretinoin for both acne and photoaging can reasonably have the prescription coded for acne.

Compounding and Specialty Access

The rise of telehealth dermatology has created a parallel market of compounded formulations. Compounded finasteride exists primarily as a topical solution (typically 0.1%, 0.25% finasteride in a minoxidil base). This topical approach may reduce systemic side effects, though evidence remains limited to small trials [6]. Compounded topical finasteride costs $30 to $80 per month, significantly more than oral generic finasteride.

Compounded tretinoin formulations are common on telehealth platforms. These typically combine tretinoin 0.02%, 0.05% with niacinamide 4%, 5%, azelaic acid 5%, 15%, and sometimes hydroquinone 4% for hyperpigmentation. Monthly costs range from $30 to $90.

A key access consideration: compounded medications cannot be substituted at retail pharmacies and must be filled by the specific compounding pharmacy partnered with the prescribing platform. This creates vendor lock-in. If a patient stops their telehealth subscription, they need a new prescription for a standard formulation to fill at a retail pharmacy.

503A compounding pharmacies (patient-specific) and 503B outsourcing facilities (batch production) operate under different regulatory frameworks. The FDA's guidance on compounding outlines these distinctions. Patients should verify that their compounding pharmacy holds proper state licensure and FDA registration.

Side Effect Costs and Monitoring

The cost equation should include monitoring and management of adverse effects. Finasteride at 1 mg daily carries a 1.3%, 3.7% incidence of sexual side effects (decreased libido, erectile dysfunction) based on the original Merck clinical trials submitted to the FDA [3]. These are generally reversible on discontinuation. Rare reports of persistent sexual side effects (post-finasteride syndrome) remain controversial and are under investigation by the NIH [7].

Monitoring costs for finasteride are minimal. No blood work is routinely required for the 1 mg dose. However, finasteride lowers PSA by approximately 50%, so prescribers should document baseline PSA before initiation in men over 40 (a $25, $50 lab test).

Tretinoin's adverse effects are local: erythema, peeling, dryness, photosensitivity. These are expected and typically peak at weeks 2 to 6 before subsiding. Managing retinoid dermatitis may require additional products (a gentle moisturizer at $8, $15, mineral sunscreen at $10, $20) that represent a real but modest ongoing cost. No laboratory monitoring is needed for topical tretinoin.

Neither drug requires specialist monitoring in routine use. Both can be safely prescribed and managed by primary care physicians, reducing access barriers compared to medications that require dermatology referral.

Patient Assistance and Discount Programs

Patients without insurance have several cost-reduction options. For finasteride, the GoodRx and RxSaver discount card programs consistently bring the price of generic finasteride 1 mg to $4 to $9 for a 30-day supply. Mark Cuban's Cost Plus Drugs lists finasteride 1 mg at $3.60 for 30 tablets (as of early 2026).

For tretinoin, discount cards are less effective because the base price is higher, but savings of 30%, 60% off retail are common. Cost Plus Drugs lists tretinoin 0.025% cream (20 g) at approximately $7.50, though the smaller tube size means more frequent refills.

Manufacturer patient assistance programs are less relevant here because both drugs are long off-patent with strong generic competition. The savings come from pharmacy shopping and discount programs rather than manufacturer coupons.

Veterans enrolled in VA healthcare receive both medications at $0 copay for service-connected conditions or at $5 copay tiers for non-service-connected conditions through the VA formulary, which includes both generic finasteride and generic tretinoin [8].

The Bottom Line on Value

The appropriate question is not "finasteride or tretinoin" but rather "do I need one, the other, or both?" They serve non-overlapping clinical purposes. A 35-year-old man with Norwood III hair loss and moderate sun damage might use finasteride 1 mg daily ($8/month) plus tretinoin 0.05% cream nightly ($30/month) for a combined out-of-pocket cost under $40 per month, with no pharmacologic interaction between the two.

For hair loss alone, finasteride offers the best cost-to-efficacy ratio of any FDA-approved treatment: $3 to $15 per month for a drug that maintained or increased hair count in 83% of men over 5 years [1]. For acne and photoaging, tretinoin at $20 to $75 per month remains the gold-standard topical retinoid, with over 50 years of clinical evidence and the lowest cost of any prescription retinoid.

Generic finasteride 1 mg at $4 per month through Cost Plus Drugs represents roughly $0.13 per day for a treatment with level-1 evidence from a 5-year RCT.